NDAINTRAVENOUSPOWDERPriority Review
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEZABY (phenobarbital sodium) is a barbiturate administered intravenously as a powder formulation. It is indicated for acute seizure management and sedation in critical care settings. Phenobarbital works as a central nervous system depressant by enhancing GABA-mediated chloride influx at neuronal membranes.
Peak15.7 years to LOE
Product is in peak commercial phase with no direct competitors, suggesting stable market position and potential for team expansion in key accounts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SEZABY represents a niche, high-barrier-to-entry product with zero direct competition and strong patent protection through 2042. Career roles focus on commercial execution in hospital and critical care channels, with emphasis on key account management and clinical support.
Brand ManagerField Sales Representative
Worked on SEZABY at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.